Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Oncology Letters
Join Editorial Board Propose a Special Issue
Print ISSN: 1792-1074 Online ISSN: 1792-1082
Journal Cover
May-2015 Volume 9 Issue 5

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
May-2015 Volume 9 Issue 5

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Lentivirus-mediated RNA interference targeting UbcH10 reduces cell growth and invasion of human osteosarcoma cells via inhibition of Ki-67 and matrix metalloproteinases

Expression of Concern in: /10.3892/ol.2025.15260
  • Authors:
    • Shan‑Tao Wang
    • Dan‑Zhi Li
    • Jian‑Min Li
    • Jun Fang
    • Hua‑Zhuang Li
    • Pei‑Jian Tong
    • Fu‑Cun Liu
  • View Affiliations / Copyright

    Affiliations: Department of Orthopedics, Qilu Hospital, Shandong University, Jinan, Shandong 510012, P.R. China, Department of Orthopedics, Yidu Central Hospital of Weifang, Qingzhou, Shandong 262500, P.R. China, Department of Orthopedics, The First Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine, Hangzhou, Zhejiang 310006, P.R. China
  • Pages: 2171-2176
    |
    Published online on: March 10, 2015
       https://doi.org/10.3892/ol.2015.3023
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Osteosarcoma (OS) is the most commonly diagnosed primary malignancy affecting the bone. UbcH10 is a cancer‑related E2‑ubiquitin‑conjugating enzyme. An overexpression of UbcH10 is significantly associated with tumor grade and cellular proliferation. However, limited evidence exists with regard to the biological function of UbcH10 in OS. The present study created a UbcH10 knockdown OS cell line using lentivirus‑mediated RNA interference. The expression of UbcH10 was significantly reduced in UbcH10‑targeted small hairpin RNA‑expressing lentivirus OS cells. The downregulation of UbcH10 suppressed OS cell proliferation and colony formation ability via decreased Ki‑67 expression. UbcH10 knockdown OS cells exhibited impaired invasion and migration abilities. Furthermore, knockdown of UbcH10 led to decreased levels of matrix metalloproteinase‑3 and ‑9 in OS cells. The present study demonstrated the role of UbcH10 in OS cell proliferation, invasion and migration, which suggests that UbcH10 may be a potential candidate for OS therapy.

Introduction

Osteosarcoma (OS) is the most commonly diagnosed primary malignant cancer affecting the bone, and one of the most heterogeneous types of human tumor (1,2). The incidence rates of OS are 1.7 per million and 4.2 per million, in individuals aged 25–59 years old and ≥60 years old, respectively (3). OS predominantly occurs in children and young adolescents, and is characterized by a high level of malignancy, relapse and metastasis, and poor prognoses. In recent years, the combination of systemic chemotherapy and modern surgery has improved the treatment of OS. However, no substantial improvement in patient survival has been observed (4) and the five-year survival rate for patients with metastatic OS is 20–30% (3). Therefore, it is important to understand the molecular mechanisms underlying OS in order to improve treatment strategies. In addition, the identification and characterization of molecules involved in OS tumorigenesis is required to aid advances in therapeutic strategies.

Ubiquitin-conjugating enzyme E2 C (UbcH10) belongs to the E2 family and is involved in ubiquitin-dependent proteolysis (5,6). UbcH10 is highly conserved and consists of a core domain with a catalytic Cys residue, and an N-terminal extension (7). The core domain interacts with a ubiquitin-fold domain in the E1 enzyme to form a ubiquitin adduct, and the N-terminal extension regulates E3 enzyme activity. Previous studies have demonstrated that UbcH10 is crucial in mitotic regulation, and is required for the degradation of mitotic checkpoint proteins, cyclins (5,8) and other mitosis-related substrates (7,9), which are essential for spindle assembly checkpoints and mitotic exits. Increasing evidence has indicated that UbcH10 is abnormally overexpressed in a number of malignant tumors, including cancers of the adrenal gland, bladder, brain, breast, cervix, colon, rectum, esophagus, liver, lung, nasopharynx, ovary, prostate (late-stage), pancreas, stomach, thyroid and uterus (10,11). UbcH10 is recognized as a potential cancer biomarker (11). An overexpression of UbcH10 is significantly associated with the pathological grading of tumors, high cellular proliferation and poor prognoses of cancers affecting the adrenal gland, breast, colon, liver, lung and ovary (10,11). Furthermore, UbcH10 transgenic mice are prone to developing a range of spontaneous and carcinogen-induced tumors (12). By contrast, silencing of UbcH10 inhibits glioma and colorectal cancer proliferation (13,14). However, limited evidence exists regarding the biological function of UbcH10 in OS.

In the present study, UbcH10 was knocked down in the OS U2OS and SaOS2 cell lines through lentivirus-mediated RNA interference (RNAi). The role of UbcH10 in OS progression was then analyzed in vitro. The cellular proliferation, invasion, colony formation and migration abilities were determined in UbcH10 knockdown cells. In addition, the expression of Ki-67 and matrix metalloproteinases (MMPs) were analyzed.

Materials and methods

Cell culture

The human OS U2OS and SaOS2 cell lines were obtained from the Institute of Biochemistry and Cell Biology (Shanghai, China). The cells were incubated in RPMI-1640 medium supplemented with 10% fetal calf serum (Thermo Fisher Scientific Inc., Waltham, MA, USA) and 1% antibiotics (penicillin and streptomycin; Sigma-Aldrich, St. Louis, MO, USA) at 37°C in a humidified 5% CO2 atmosphere.

Lentivirus-mediated short hairpin RNA (shRNA) transfection

The shRNA oligos of UbcH10 were designed according to its sequence in the NCBI database as follows: 5′-AACCUGCAAGAAACCUACUCA-dTdT-3′. The sequence of the control shRNA was as follows: 5′-AAAUGCACACACACAUACUCG-dTdT-3′. The fragments of shRNA were inserted into the lentivirus vector and transfected into HEK293 cells with packaging vectors using Lipofectamine 2000 (Life Technologies, Grand Island, NY, USA). After 48 h, the recombinant lentivirus was collected from the media for further infection.

The U2OS and SaOS2 cells were cultured in a 6-well plate at a density of 12×104 cells per well. Subsequent to a 24-h culture, the cells were transfected with the recombinant lentivirus at a multiplicity of infection of 20. At 48 h post-infection, the cells were observed using a fluorescence microscope (DM IL LED; Leica Microsystems, Wetzlar, Germany). The infection efficiencies were determined by the ratio of green fluorescent protein (GFP)-positive cells to total cells.

Western blot analysis

At 3 days post lentiviral infection, the U2OS and SaOS2 cells were collected and lysed in RIPA buffer (150 mM NaCl, 100 mM Tris-HCl, 1% Tween-20, 1% sodium deoxycholate and 0.1% SDS) supplemented with 1 mM phenylmethylsulfonyl fluoride (PMSF) and a protease inhibitor cocktail. Following centrifugation at 13,000 × g for 15 min, the supernatant was collected and boiled with 2X SDS protein sample buffer. The proteins were separated using SDS-PAGE and transferred to polyvinylidene fluoride membranes. The membranes were blocked with Tris-buffered saline and Tween 20 (TBST; Beijing SolarBio Science & Technology Co., Ltd., Beijing, China) plus 1% bovine serum albumin (Westang Bio-Tech Co., Ltd., Shanghai, China) for 1 h and probed with a variety of antibodies overnight at 4°C. Next, the membranes were washed with TBST for 15 min and probed with horseradish peroxidase-conjugated secondary antibodies for 1 h. The membranes were then washed with TBST for 15 min and signals were detected by enhanced chemiluminescence using SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific Inc.) and the Amersham Imager 600 (GE Healthcare, Pittsburgh, PA, USA). The primary antibodies used in the present study were: Anti-UbcH10 (1:500; cat. no. 14234S; Cell Signaling Technology, Inc., Danvers, MA, USA), anti-GAPDH (1:10,000; cat. no. sc-365062; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), anti-Ki-67 (1:1,000; cat. no. sc-7846; Santa Cruz Biotechnology, Inc.), anti-MMP-3 (1:1,000; cat. no. 14351S; Cell Signaling Technology, Inc.) and anti-MMP-9 (1:1,000; cat. no. sc-21733; Santa Cruz Biotechnology, Inc.). The secondary antibodies were horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin G (1:2,000; cat. no. sc-2004; Santa Cruz Biotechnology, Inc.).

MTT assay

In brief, the U2OS and SaOS2 cells were cultured in a 96-well plate at a density of 104 cells per well. Subsequent to a 24-h incubation, the cells were transfected with a recombinant lentivirus carrying shRNA. At various time-points of 1, 2, 3, 4 and 5 days, MTT (Sigma-Aldrich) was added at a final concentration of 5 mg/ml and incubated with the cells at 37°C for 4 h. After removing the medium, dimethyl sulfoxide was added in order to terminate the reaction. All wells were analyzed using an ELISA reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA) at a wavelength of 490 nm.

Colony formation assay

After 5 days of lentivirus treatment with control shRNA-expressing lentivirus (Lv-shCon) or UbcH10-targeted shRNA-expressing lentivirus (Lv-shUbcH10), the U2OS and SaOS2 cells were trypsinized, counted and then replated in a 6-well plate at a concentration of 200 cells per well. The cell samples were then allowed to grow for 14 days in order to form natural colonies. Following this, the plate was washed twice with phosphate-buffered saline solution and stained for 10 min with Giemsa (Sigma-Aldrich). Images of the stained colonies were then captured under a fluorescence microscope. Finally, the total number of colonies (N50 cells/colony) and the total number of cells in each colony were counted and analyzed.

Transwell invasion assay

The invasion of U2OS and SaOS2 cells was analyzed using BioCoat Transwell chambers (Corning Incorporated, Corning, New York, NY, USA). The cells were serum starved for 24 h and then harvested. In total, 2×104 cells were added to the upper chamber, which was coated with Matrigel™ matrix (BD Biosciences, Franklin Lakes, NJ, USA). Subsequent to a 24-h incubation at 37°C in a humidified atmosphere of 5% CO2, the cells on the upper surface of the chamber were removed with a cotton swab. The cells that had invaded to the bottom surface of the insert were fixed with 70% ethanol and stained with crystal violet. The invasiveness was quantitated by counting the number of cells on five different random views using a light microscope (DMi1; Leica Microsystems) (magnification, x10). All experiments were repeated at least three times, with more than three wells for each treatment.

Migration assay

Cellular migration was analyzed using a wound healing assay. The U2OS and SaOS2 cells were cultured to 90–95% confluence and then serum starved for 24 h. Following this, the monolayers of cells were carefully wounded using sterilized pipette tips. The wound closure was determined using a light microscope, and images were captured at the indicated time points.

Statistical analysis

The cell culture experiments were performed in triplicate. Student's t-test was used to analyze the significance of differences. Two-tailed P<0.05 was considered to indicate a statistically significant difference, and the data are presented as the mean ± standard deviation.

Results

Lentivirus-mediated RNAi efficiently suppresses the expression of UbcH10 in OS cells

At 24 h post lentivirus-transfection, >90% Lv-shCon and Lv-ShUbcH10 transfected U2OS and SaOS2 cells exhibited GFP-positive signals (Fig. 1A), which indicated that the recombinant lentivirus was able to infect the OS cells with high efficiency. The proportion of positive cells that were transfected with Lv-shUbcH10 was >90%, as evidenced by GFP expression 3 days after transfection (Fig. 1A). Further western blot analysis revealed that the protein levels of UbcH10 were significantly reduced in Lv-shUbcH10-transfected U2OS and SaOS2 cells (P=0.018 and P=0.021, respectively; Fig. 1B–E). The control shRNA did not affect the expression of UbcH10. These data demonstrate the high gene transfer efficiency of lentiviruses in OS cells, and suggest that the expression of UbcH10 is efficiently knocked down by shUbcH10.

Figure 1.

UbcH10 expression is suppressed in osteosarcoma cells by lentivirus-mediated RNA interference. (A) Representative images of Con, and Lv-shCon- and Lv-shUbcH10-transfected OS cells captured under a fluorescence microscope. Upper panel, bright field; lower panel, GFP. Western blotting analysis revealing the protein levels of UbcH10 in Con, and Lv-shCon- and Lv-shUbcH10-transfected (B) SaOS2 cells and (C) U2OS cells. GAPDH was used as a control protein. Calculation of UbcH10 protein levels in (D) SaOS2 cells and (E) U2OS cells (normalized to GAPDH). *P<0.05 vs. the control group. Con, control; Lv-shCon, control small hairpin RNA-expressing lentivirus; Lv-shUbcH10, UbcH10-targeted small hairpin RNA-expressing lentivirus; GFP, green fluorescent protein.

UbcH10-targeted RNAi reduces OS cell proliferation and colony formation

Proliferation is a key process involved in the progression of tumors. In order to determine whether shUbcH10 has an inhibitory effect upon OS cell growth, an MTT assay was performed. As shown in Fig. 2A and B, the growth curves for UbcH10 knockdown U2OS and SaOS2 cells were significantly lower during the 5-day incubation than those for control cells and Lv-shCon-transfected cells (P=0.0017 and P=0.0028, respectively). The colony formation assay demonstrated that the colony numbers of Lv-shUbcH10-transfected U2OS and SaOS2 cells were significantly reduced compared with those of the control cells and Lv-shCon-transfected cells (P=0.0015 and P=0.0022, respectively) (Fig. 2C and D). This indicates that the colony formation ability is impaired in UbcH10 knock-down OS cells.

Figure 2.

UbcH10-targeted RNA interference reduces osteosarcoma cellular proliferation and colony formation. Results of the MTT assay revealing the cellular proliferation of Con, and Lv-shCon- and Lv-shUbcH10-transfected (A) SaOS2 cells and (B) U2OS cells. (C) Representative images revealing the crystal violet-stained colonies of Con, and Lv-shCon- and Lv-shUbcH10-transfected SaOS2 and U2OS cells. (D) Calculation of colony numbers of Con, and Lv-shCon- and Lv-shUbcH10-transfected SaOS2 and U2OS cells. (E) Western blot analysis revealing the protein levels of Ki-67 in Con, and Lv-shCon- and Lv-shUbcH10-transfected SaOS2 and U2OS cells. GAPDH was used as a control protein. (F) Calculation of Ki-67 protein levels in SaOS2 and U2OS cells, normalized to GAPDH. **P<0.01 vs. the control group. Con, control; Lv-shCon, control small hairpin RNA-expressing lentivirus; Lv-shUbcH10, UbcH10-targeted small hairpin RNA-expressing lentivirus; OD, optical density.

To confirm the results, western blotting was performed in order to analyze the expression level of the cellular proliferation marker, Ki-67. As shown in Fig. 2E and F, there was no significant difference in the protein level of Ki-67 in Lv-shCon-transfected U2OS and SaOS2 cells (P=0.657). By contrast, the expression of Ki-67 was markedly reduced in UbcH10 knock-down U2OS and SaOS2 cells (P=0.0035 and P=0.0017, respectively). These results indicate that fewer OS cells entered the process of proliferation following downregulation of UbcH10, a result is which is consistent with those of the MTT and colony formation assays.

UbcH10-targeted RNAi suppresses OS cell invasion and migration

The matrix invasion and migration abilities of cancer cells are closely associated with metastasis. Therefore, the effect of UbcH10 suppression on the invasion of OS cells was investigated. The results of the Transwell invasion assay revealed fewer UbcH10 knock-down U2OS and SaOS2 cells than control and Lv-shCon-transfected U2OS and SaOS2 cells in the lower chamber (Fig. 3A and B). The cell migration was investigated using a wound healing assay. The quantification of cellular movement at 24 h revealed that cellular migration was significantly repressed in UbcH10 knock-down U2OS and SaOS2 cells compared with control and Lv-shCon-transfected cells (P=0.0029 and P=0.0016, respectively) (Fig. 3C and D). These results suggest that the invasion and migration abilities of OS cells are impaired following knockdown of UbcH10.

Figure 3.

UbcH10-targeted RNA interference reduces osteosarcoma cell proliferation and colony formation. (A, B) MTT assay revealing the cellular proliferation of Con, and Lv-shCon- and Lv-shUbcH10-transfected SaOS2 and U2OS cells. **P<0.01 vs. the control group. (C) Representative images revealing crystal violet-stained colonies of Con, and Lv-shCon- and Lv-shUbcH10-transfected SaOS2 and U2OS cells. (D) Calculation of colony numbers of Con, and Lv-shCon- and Lv-shUbcH10-transfected SaOS2 and U2OS cells. **P<0.01 vs. the control group. Con, control; Lv-shCon, control small hairpin RNA-expressing lentivirus; Lv-shUbcH10, UbcH10-targeted small hairpin RNA-expressing lentivirus.

UbcH10 knockdown of OS cells downregulates the expression of MMPs

The expression of MMPs in U2OS and SaOS2 cells was investigated. The levels of MMP-3 protein were significantly reduced in Lv-shUbcH10-transfected U2OS and SaOS2 cells compared with control and Lv-shCon-transfected cells (P=0.0043 and P=0.0061, respectively) (Fig. 4A–C). Similar results were observed for MMP-9 (Fig. 4D–F). These results indicate that the MMP signaling pathway is disrupted in UbcH10 knockdown OS cells.

Figure 4.

Protein levels of MMP-3 and −9 are downregulated in UbcH10 knock-down osteosarcoma cells. Western blot analysis showing the protein levels of MMP-3 in Con, and Lv-shCon- and Lv-shUbcH10-transfected (A) SaOS2 cells and (B) U2OS cells. GAPDH was used as a control protein. (C) Calculation of MMP-3 protein levels in SaOS2 and U2OS cells, normalized to GAPDH. **P<0.01 vs. the control group. Western blot analysis showing the protein levels of MMP-9 in Con, and Lv-shCon-and Lv-shUbcH10-transfected (C) SaOS2 cells and (D) U2OS cells. GAPDH was used as a control protein. (F) Calculation of MMP-9 protein levels in SaOS2 and U2OS cells, normalized to GAPDH. **P<0.01 vs. the control group. MMP, matrix metalloproteinase; Con, control; Lv-shCon, control small hairpin RNA-expressing lentivirus; Lv-shUbcH10, UbcH10-targeted small hairpin RNA-expressing lentivirus.

Discussion

UbcH10 is a potential cancer biomarker that is overexpressed in a variety of cancers. In order to investigate its functions in OS, UbcH10 was knocked down in the OS U2OS and SaOS2 cell lines. Western blot analysis revealed that the protein levels of UbcH10 in Lv-shUbcH10 decreased to approximately one quarter of that in the control cells. This indicated that the recombinant lentivirus containing UbcH10-targeted shRNA could successfully knockdown UbcH10 in U2OS and SaOS2 cells. Lentiviruses are therefore useful for gene-targeted RNAi in OS cells in vitro.

The present study also identified that, as a result of decreased Ki-67 levels, a downregulation in the expression of UbcH10 inhibited cellular proliferation and colony formation in vitro. This confirmed that the expression of UbcH10 is correlated with the proliferation activity of cancer cells. In accordance with the results of the present study, a previous study demonstrated that a knockdown of UbcH10 inhibited the cellular proliferation of other cancer cells, including those of lung, glioma and colorectal cancers (13–15). It is therefore hypothesized that OS cell growth inhibition is caused by UbcH10-mediated cell cycle regulation. In order to address this, the present study analyzed the expression of the cellular proliferation marker, Ki-67 (16). Following UbcH10 knockdown, the decreased expression of Ki-67 indicated the presence of fewer dividing OS cells. This is consistent with its role in the regulation of mitotic exit and cell cycle progression through the destruction of mitosis-related substrates (5,7–9).

A downregulation in the expression of UbcH10 was also observed to impair the invasion and migration ability of OS cells. In lung cancer cells, UbcH10-targeted RNAi also inhibits cellular migration (15). In order to determine the underlying mechanisms involved in the impaired invasion and migration of UbcH10 knockdown OS cells, the expression of MMP-3 and MMP-9 was analyzed. The levels of MMP-3 and −9 proteins decreased significantly. MMPs are a family of zinc-dependent endopeptidases, which degrade proteins in the extracellular matrix (17), and are crucial in cancer cell invasion and migration (17,18). Previous studies have demonstrated that an overexpression of MMP-3 in normal breast epithelium results in invasive tumor formation (19). Additionally, in a recent study, MMP-9 was identified as a potential biomarker for OS (20). The downregulation of MMP-3 and −9 confirms that tumorigenesis is inhibited in UbcH10 knockdown OS cells. However, whether MMP-3 and −9 are direct substrates of UbcH10-mediated ubiquitin-dependent proteolysis remains to be elucidated.

In conclusion, the results of the present study demonstrate that, via the deregulation of Ki-67 and MMPs, lentivirus-mediated UbcH10-targeted RNAi can lead to cell growth inhibition, decreased colony formation, and impaired cellular invasion and migration in the human OS U2OS and SaOS2 cell lines. These results indicate an important role for UbcH10 in OS progression, which suggests that UbcH10 may be a potential therapeutic target for the treatment of OS. Therapeutic strategies which target the UbcH10 gene or compounds that inhibit UbcH10 activity may be of use clinically for the treatment of OS and thus, further studies are required to investigate these methods.

References

1 

Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A and Picci P: Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 106:1154–1161. 2006. View Article : Google Scholar : PubMed/NCBI

2 

Ottaviani G and Jaffe N: The etiology of osteosarcoma. Cancer Treat Res. 152:15–32. 2009. View Article : Google Scholar : PubMed/NCBI

3 

Mirabello L, Troisi RJ and Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI

4 

Akiyama T, Dass CR and Choong PF: Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway. Mol Cancer Ther. 7:3461–3469. 2008. View Article : Google Scholar : PubMed/NCBI

5 

Townsley FM, Aristarkhov A, Beck S, Hershko A and Ruderman JV: Dominant-negative cyclin-selective ubiquitin carrier protein E2-C/UbcH10 blocks cells in metaphase. Proc Natl Acad Sci USA. 94:2362–2367. 1997. View Article : Google Scholar : PubMed/NCBI

6 

Okamoto Y, Ozaki T, Miyazaki K, Aoyama M, Miyazaki M and Nakagawara A: UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme. Cancer Res. 63:4167–4173. 2003.PubMed/NCBI

7 

Lin Y, Hwang WC and Basavappa R: Structural and functional analysis of the human mitotic-specific ubiquitin-conjugating enzyme, UbcH10. J Biol Chem. 277:21913–21921. 2002. View Article : Google Scholar : PubMed/NCBI

8 

Aristarkhov A, Eytan E, Moghe A, Admon A, Hershko A and Ruderman JV: E2-C, a cyclin-selective ubiquitin carrier protein required for the destruction of mitotic cyclins. Proc Natl Acad Sci USA. 93:4294–4299. 1996. View Article : Google Scholar : PubMed/NCBI

9 

Rape M, Reddy SK and Kirschner MW: The processivity of multiubiquitination by the APC determines the order of substrate degradation. Cell. 124:89–103. 2006. View Article : Google Scholar : PubMed/NCBI

10 

Hao Z, Zhang H and Cowell J: Ubiquitin-conjugating enzyme UBE2C: molecular biology, role in tumorigenesis, and potential as a biomarker. Tumour Biol. 33:723–730. 2012. View Article : Google Scholar : PubMed/NCBI

11 

Xie C, Powell C, Yao M, Wu J and Dong Q: Ubiquitin-conjugating enzyme E2C: a potential cancer biomarker. Int J Biochem Cell Biol. 47:113–117. 2014. View Article : Google Scholar : PubMed/NCBI

12 

van Ree JH, Jeganathan KB, Malureanu L and van Deursen JM: Overexpression of the E2 ubiquitin-conjugating enzyme UbcH10 causes chromosome missegregation and tumor formation. J Cell Biol. 188:83–100. 2010. View Article : Google Scholar : PubMed/NCBI

13 

Jiang L, Bao Y, Luo C, et al: Knockdown of ubiquitin-conjugating enzyme E2C/UbcH10 expression by RNA interference inhibits glioma cell proliferation and enhances cell apoptosis in vitro. J Cancer Res Clin Oncol. 136:211–217. 2010. View Article : Google Scholar : PubMed/NCBI

14 

Chen SM, Jiang CY, Wu JY, et al: RNA interference-mediated silencing of UBCH10 gene inhibits colorectal cancer cell growth in vitro and in vivo. Clin Exp Pharmacol Physiol. 37:525–529. 2010. View Article : Google Scholar : PubMed/NCBI

15 

Pallante P, Malapelle U, Berlingieri MT, et al: UbcH10 overexpression in human lung carcinomas and its correlation with EGFR and p53 mutational status. Eur J Cancer. 49:1117–1126. 2013. View Article : Google Scholar : PubMed/NCBI

16 

Scholzen T and Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol. 182:311–322. 2000. View Article : Google Scholar : PubMed/NCBI

17 

Kleiner DE and Stetler-Stevenson WG: Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol. 43:Suppl. S42–S51. 1999. View Article : Google Scholar : PubMed/NCBI

18 

Davies KJ: The complex interaction of matrix metalloproteinases in the migration of cancer cells through breast tissue stroma. Int J Breast Cancer. 2014:8390942014. View Article : Google Scholar : PubMed/NCBI

19 

Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2:161–174. 2002. View Article : Google Scholar : PubMed/NCBI

20 

Wang J, Shi Q, Yuan TX, et al: Matrix metalloproteinase 9 (MMP-9) in osteosarcoma: review and meta-analysis. Clin Chim Acta. 433:225–231. 2014. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Wang ST, Li DZ, Li JM, Fang J, Li HZ, Tong PJ and Liu FC: Lentivirus-mediated RNA interference targeting UbcH10 reduces cell growth and invasion of human osteosarcoma cells via inhibition of Ki-67 and matrix metalloproteinases Expression of Concern in /10.3892/ol.2025.15260. Oncol Lett 9: 2171-2176, 2015.
APA
Wang, S., Li, D., Li, J., Fang, J., Li, H., Tong, P., & Liu, F. (2015). Lentivirus-mediated RNA interference targeting UbcH10 reduces cell growth and invasion of human osteosarcoma cells via inhibition of Ki-67 and matrix metalloproteinases Expression of Concern in /10.3892/ol.2025.15260. Oncology Letters, 9, 2171-2176. https://doi.org/10.3892/ol.2015.3023
MLA
Wang, S., Li, D., Li, J., Fang, J., Li, H., Tong, P., Liu, F."Lentivirus-mediated RNA interference targeting UbcH10 reduces cell growth and invasion of human osteosarcoma cells via inhibition of Ki-67 and matrix metalloproteinases Expression of Concern in /10.3892/ol.2025.15260". Oncology Letters 9.5 (2015): 2171-2176.
Chicago
Wang, S., Li, D., Li, J., Fang, J., Li, H., Tong, P., Liu, F."Lentivirus-mediated RNA interference targeting UbcH10 reduces cell growth and invasion of human osteosarcoma cells via inhibition of Ki-67 and matrix metalloproteinases Expression of Concern in /10.3892/ol.2025.15260". Oncology Letters 9, no. 5 (2015): 2171-2176. https://doi.org/10.3892/ol.2015.3023
Copy and paste a formatted citation
x
Spandidos Publications style
Wang ST, Li DZ, Li JM, Fang J, Li HZ, Tong PJ and Liu FC: Lentivirus-mediated RNA interference targeting UbcH10 reduces cell growth and invasion of human osteosarcoma cells via inhibition of Ki-67 and matrix metalloproteinases Expression of Concern in /10.3892/ol.2025.15260. Oncol Lett 9: 2171-2176, 2015.
APA
Wang, S., Li, D., Li, J., Fang, J., Li, H., Tong, P., & Liu, F. (2015). Lentivirus-mediated RNA interference targeting UbcH10 reduces cell growth and invasion of human osteosarcoma cells via inhibition of Ki-67 and matrix metalloproteinases Expression of Concern in /10.3892/ol.2025.15260. Oncology Letters, 9, 2171-2176. https://doi.org/10.3892/ol.2015.3023
MLA
Wang, S., Li, D., Li, J., Fang, J., Li, H., Tong, P., Liu, F."Lentivirus-mediated RNA interference targeting UbcH10 reduces cell growth and invasion of human osteosarcoma cells via inhibition of Ki-67 and matrix metalloproteinases Expression of Concern in /10.3892/ol.2025.15260". Oncology Letters 9.5 (2015): 2171-2176.
Chicago
Wang, S., Li, D., Li, J., Fang, J., Li, H., Tong, P., Liu, F."Lentivirus-mediated RNA interference targeting UbcH10 reduces cell growth and invasion of human osteosarcoma cells via inhibition of Ki-67 and matrix metalloproteinases Expression of Concern in /10.3892/ol.2025.15260". Oncology Letters 9, no. 5 (2015): 2171-2176. https://doi.org/10.3892/ol.2015.3023
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team